In this study, patients with heterogeneous ARID1A expression in the primary tumor showed different lymph node metastases staining patterns as diverse as complete loss of ARID1A (53.2%), retained expression (21.3%), and heterogeneous expression (25.5%) [75]. This evidence concerns the gene ARID1A and neoplasm.